128 related articles for article (PubMed ID: 22027748)
1. Diagnostic implications of p16 expression in serous papillary endometrial cancer.
Netzer IM; Kerner H; Litwin L; Lowenstein L; Amit A
Int J Gynecol Cancer; 2011 Nov; 21(8):1441-5. PubMed ID: 22027748
[TBL] [Abstract][Full Text] [Related]
2. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
3. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
4. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma.
Zheng W; Khurana R; Farahmand S; Wang Y; Zhang ZF; Felix JC
Am J Surg Pathol; 1998 Dec; 22(12):1463-73. PubMed ID: 9850172
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
6. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein.
Armes JE; Lourie R; de Silva M; Stamaratis G; Boyd A; Kumar B; Price G; Hyde S; Allen D; Grant P; Venter DJ
Int J Gynecol Pathol; 2005 Oct; 24(4):363-8. PubMed ID: 16175083
[TBL] [Abstract][Full Text] [Related]
8. Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases.
Wei JJ; Paintal A; Keh P
Arch Pathol Lab Med; 2013 Nov; 137(11):1574-83. PubMed ID: 24168495
[TBL] [Abstract][Full Text] [Related]
9. Stromal p16 expression is significantly increased in endometrial carcinoma.
Yoon G; Koh CW; Yoon N; Kim JY; Kim HS
Oncotarget; 2017 Jan; 8(3):4826-4836. PubMed ID: 27902476
[TBL] [Abstract][Full Text] [Related]
10. A "Null" Pattern of p16 Immunostaining in Endometrial Serous Carcinoma: An Under-recognized and Important Aberrant Staining Pattern.
Matson DR; Accola MA; Henderson L; Shao X; Frater-Rubsam L; Horner VL; Rehrauer WM; Weisman P; Xu J
Int J Gynecol Pathol; 2022 Jul; 41(4):378-388. PubMed ID: 34380970
[TBL] [Abstract][Full Text] [Related]
11. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
Konecny GE; Agarwal R; Keeney GA; Winterhoff B; Jones MB; Mariani A; Riehle D; Neuper C; Dowdy SC; Wang HJ; Morin PJ; Podratz KC
Gynecol Oncol; 2008 May; 109(2):263-9. PubMed ID: 18313739
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
13. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
14. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
15. PAX2 and cyclin D1 expression in the distinction between cervical microglandular hyperplasia and endometrial microglandular-like carcinoma: a comparison with p16, vimentin, and Ki67.
Stewart CJ; Crook ML
Int J Gynecol Pathol; 2015 Jan; 34(1):90-100. PubMed ID: 25473758
[TBL] [Abstract][Full Text] [Related]
16. P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.
Caponio MA; Addati T; Popescu O; Petroni S; Rubini V; Centrone M; Trojano G; Simone G
Cancer Biomark; 2014; 14(2-3):169-75. PubMed ID: 24878818
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
[TBL] [Abstract][Full Text] [Related]
18. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
19. Endometrioid Endometrial Carcinoma With Spindle Cells-Aberrant p16 and p53 Expression.
Sonawane S; Elfituri O; Zhang Y; Yordan E; Ree N
Int J Surg Pathol; 2019 Apr; 27(2):203-207. PubMed ID: 29953305
[TBL] [Abstract][Full Text] [Related]
20. Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation.
Ussakli C; Usubutun A; Dincer N; Dolgun A; Bülbül D; Isikdogan Z; Haberal N; Ozen O; Tezel GG
Pol J Pathol; 2016; 67(3):221-227. PubMed ID: 28155970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
